The IL-12- inducible GPC3-CAR-T cells could broaden the application of CAR-T-based immunotherapy to patients intolerant of cytoreductive chemotherapy and might provide an alternative therapeutic strategy for patients with GPC3+cancers [150]. Here, GPC3 is linked to cancer.